Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05350553 · ClinicalTrials.gov registry record

Methylglyoxal Evaluation in Humans

A clinical trial of Type 2 Diabetes and Chronic Low Back Pain, sponsored by University of Kansas Medical Center.

Completed
Registry status
39
Enrollment target
1
Study location

NCT05350553: Completed study of Type 2 Diabetes and Chronic Low Back Pain, sponsored by University of Kansas Medical Center.

NCT05350553 is a study of Type 2 Diabetes and Chronic Low Back Pain that has completed, run by University of Kansas Medical Center. The registered enrollment target is 39 participants, below the 3,924-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05350553, a study of Type 2 Diabetes and Chronic Low Back Pain, has completed, sponsored by University of Kansas Medical Center.

COMPLETED
Registry status
39 participants
Enrollment target
1
Study location

Study Summary

The investigators will test the hypothesis that patients with low back pain associated with lumbar disc aberrancy will have elevated MGO-protein levels circulating in the blood that are comparable to patients with painful diabetic neuropathy.

Primary Outcome

Number of participants with elevated blood methylglyoxal-derived hydroimidazolone (MG-H1, nM) with chronic pain.

Study Locations (1)

Kansas

  • University of Kansas Medical Center - Kansas City

Trial Details

FieldValue
Enrollment Target 39 participants
Start Date 2022-05-02
Est. Completion 2025-04-01
University of Kansas Medical Center

408 total trials

What the finished NCT05350553 record still lists

NCT05350553 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 3,924-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (99% lower).

The record links to 4 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 0 interventions.

NCT05350553 reports a single indexed study location in Kansas.

Frequently Asked Questions

What is clinical trial NCT05350553 about?

NCT05350553 is a clinical study titled "Methylglyoxal Evaluation in Humans". The investigators will test the hypothesis that patients with low back pain associated with lumbar disc aberrancy will have elevated MGO-protein levels circulating in the blood that are comparable to patients with painful diabetic neuropathy.

What is the current status of trial NCT05350553?

This trial is currently completed. The enrollment target is 39 participants. The study started on 2022-05-02. Estimated completion is 2025-04-01.

What conditions does trial NCT05350553 study?

This clinical trial studies the following conditions: Type 2 Diabetes, Chronic Low Back Pain, Lumbar Disc Herniation, Neuropathy, Painful.

Who is sponsoring clinical trial NCT05350553?

This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05350553 being conducted?

This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 2 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05350553's enrollment target sits among peer trials

39 241st of 327 higher than 86 of 327 other Type 2 Diabetes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03465592 · 39 participants · Phase 1

    Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma

  • NCT03961776 · 39 participants

    Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems

  • NCT04050280 · 39 participants · Phase 2

    CLAG-GO for Patients With Persistent, Relapsed or Refractory AML

  • NCT04190862 · 39 participants · Phase 1

    E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05350553, the US trial registry maintained by the National Library of Medicine. NCT05350553 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.